Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2019 at "Asia-Pacific Journal of Clinical Oncology"
DOI: 10.1111/ajco.13154
Abstract: The open‐label, nonrandomized, phase II APEC study enrolled 167 patients with RAS wild‐type (wt) metastatic colorectal cancer (mCRC) to investigate the safety and efficacy of first‐line, every‐2‐weeks cetuximab plus investigator's choice of FOLFIRI or FOLFOX… read more here.
Keywords: phase apec; metastatic colorectal; ras wild; type metastatic ... See more keywords